05:25 EDT Gilead (GILD) drops 3% to $107 after WSJ report of HIV funding cuts
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Trump administration weighs major cuts to HIV prevention funding, WSJ reports
- Trump’s Escalating Trade War Hammers Consumer Sentiment
- Why Barclays Just Increased Its 2025 Interest Rate Cut Predictions
- Market Worries? Goldman Sachs Names the Most Stable Stocks to Buy Now
- Gilead presents data for once-yearly lenacapavir for HIV prevention